Santen Pharmaceutical Co., Ltd. (OTCMKTS:SNPHY – Get Free Report) was the recipient of a significant increase in short interest in the month of July. As of July 31st, there was short interest totaling 3,813 shares, an increase of 90.3% from the July 15th total of 2,004 shares. Currently, 0.0% of the company’s shares are sold short. Based on an average daily volume of 7,078 shares, the days-to-cover ratio is presently 0.5 days.
Santen Pharmaceutical Stock Performance
Shares of Santen Pharmaceutical stock remained flat at $12.03 on Monday. 1,420 shares of the stock traded hands, compared to its average volume of 2,978. Santen Pharmaceutical has a 1 year low of $9.22 and a 1 year high of $13.93. The firm has a 50 day moving average of $12.52 and a 200-day moving average of $11.63.
About Santen Pharmaceutical
Santen Pharmaceutical Co, Ltd. is a Japan‐based specialty pharmaceutical company focused exclusively on ophthalmology. Headquartered in Osaka, Santen engages in the research, development, manufacture and marketing of prescription and over‐the‐counter products for the diagnosis and treatment of eye diseases. Its core product portfolio includes therapies for glaucoma, dry eye, retinal disorders, uveitis and post‐operative care, as well as surgical equipment and diagnostic agents designed to support comprehensive eye care.
With roots tracing back to the late 19th century, Santen has grown from a domestic manufacturer to a global ophthalmic specialist.
See Also
- Five stocks we like better than Santen Pharmaceutical
- Looking Beyond CrowdStrike? 3 AI Security Stocks Stand Out
- 5 Recession-Proof Stocks Hiding in Cardboard Boxes
- These 5 Dividend Stocks Show Why Income Investing Still Matters
- The Quantum Race Is Heating Up—And 2 Small Players Stand Out
Receive News & Ratings for Santen Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Santen Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
